PHT Corporation has announced the promotion of Dr. Susan M. Dallabrida to vice president of clinical science and consulting services. PHT is the leading provider of technologies used to collect patient-driven eData for clinical research.

Dallabrida is a daughter of Karen and Don Dallabrida, of Wilburton, and a granddaughter, of Marion Wydra, of Mount Carmel. Her sisters are Jen Kindred, of Wisconsin, and Deb Kane, of Kulpmont. She has two nieces, Alexis Kane and Kami Kindred, and a nephew, Frank Kane.

"Susan is a prominent leader and scientist dedicated to increasing industry education and awareness on the advantages that electronic clinical outcome assessment systems provide to research teams, sponsors and regulators," said Philip Lee, PHT president and CEO.

PHT Corporation is the eClinical innovator leading the adoption of patient-driven mobile apps for better clinical research. The PHT electronic clinical outcome assessment (eCOA) system collects and reports secure real-time patient data from the latest mobile devices. PHT scientific, regulatory and technological expertise combined with quality outcomes data enable clients to make research decisions with confidence. Sponsors and CROs have leveraged the PHT Patient Suite in 650+ trials resulting in 16+ regulatory approvals.

Dallabrida has more than 21 years of experience as a senior scientist, consultant and director in clinical research and development, trial design and strategy and product development.

"Susan has helped clients to better leverage their investment in eCOA by providing evidence, data analysis and creative solutions that have resulted in better study designs," Lee added.

Under Dallabrida's leadership, the clinical science and consulting team is focused on three key areas: discovery and innovation, rolling out new products targeted at improved health care in key therapeutic areas including cardiovascular disease and quantitative research to support a more patient-centric approach. This research will streamline eCOA collection and use, and as such, facilitate the determination of whether a new drug or therapy has a measureable clinical benefit.

"As a scientist, my goal is to conduct research and provide evidence that demonstrates the best and most effective paths for our clients to collect the highest quality data," she explained.

Dallabrida has led cross-functional drug discovery and product development teams and collaborations in a wide range of therapeutic areas including oncology, cardiovascular disease, hemophilia, dermatology, obesity and vascular disorders. She has significant regulatory experience in the U.S. and internationally for biologics and small molecules. She has a broad background in scientific presentations and writing with 20 publications, 14 grants, three patents, 18 awards, 35 conference presentations and 29 abstracts to her credit.